Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041)

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 636-642

  Nomura, H ^a   Aoki, D ^a   Takahashi, F ^b   Katsumata, N ^c   Watanabe, Y ^d   Konishi, I ^e   Jobo, T ^f   Hatae, M ^g   Hiura, M ^h   Yaegashi, N ⁱ  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Social Insurance Sagamino Hospital   (Japan)

^g Kagoshima City Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced; Endometrial carcinoma; Recurrent; Taxane plus platinum combination

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDRONEPHROSIS; HYPOKALEMIA; LEUKOCYTE COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ENDOMETRIUM TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; CANCER GROWTH; CANCER SURVIVAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; LEUKOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CISPLATIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 79952027743     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq401     Document Type: Article

References (30)

1. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): 105-143.
2. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36-44.
3. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984; 17: 85-103.
4. Podratz KC, O'Brien PC, Malkasian GD, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985; 66: 106-110.
5. Seski JC, Edwards CL, Hersen J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982; 59: 225-228.
6. Thigpen JT, Blessing JA, Lagasse LD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. Am J Clin Oncol 1984; 7: 253-256.
7. Thigpen JT, Blessing JA, Homesley H, et al. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 33: 68-70.
8. Long HJ, Pfeifle DM, Wieand HS, et al. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988; 80: 276-278.
9. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with single agent carboplatin. Gynecol Oncol 1993; 51: 397-400.
10. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63: 21-27.
11. Calero F, Asins-Codoner E, Jimeno J, et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 1991; 27: 864-866.
12. Pierga JY, Dieras V, Paraiso D, et al. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study. Gynecol Oncol 1996; 60: 59-63.
13. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3902-3908.
14. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448.
15. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278-281.
16. Katsumata N, Noda K, Nozawa S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer 2005; 93: 999-1004.
17. Lissoni A, Zanetta G, Losa G, et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7: 861-863.
18. Gü nthert AR, Pilz S, Kuhn W, et al. Docetaxel is effective in the treatment of metastatic endometrial cancer. Anticancer Res 1999; 19: 3459-3462.
19. Gü nthert AR, Ackermann S, Beckmann MW, et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol 2007; 104: 86-90.
20. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15: 1173-1178.
21. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-2166.
22. du Bois A, Lü ck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Natl Cancer Inst 2003; 95: 1320-1329.
23. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19: 4048-4053.
24. Sorbe B, Andersson H, Boman K, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008; 18: 803-808.
25. Markman M, Kennedy A, Webster K, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001; 19: 1901-1905.
26. Aoki D, Watanabe Y, Jobo T, et al. Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. Anticancer Res 2009; 29: 561-566.
27. Chu Q, Vincent M, Logan D, et al. Taxanes as first-line therapy for advanced nonsmall cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005; 50: 355-374.
28. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004; 9: 16-23.
29. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
30. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.